x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 Minutes

Your daily pharmaceutical news briefing — FDA decisions, clinical trial results, biotech M&A, and drug pipeline updates in under 15 minutes, every weekday. Hosted by Alex Mercer and Maya Patel. Plus a Week in Review every Sunday synthesizing the week"s biggest moves in pharma and biotech. Covering drug approvals, pharma industry deals, biopharma investing, and healthcare market intelligence. Smart, fast, and built for professionals who need to stay ahead. Hosts voices are AI created.

science life sciences

All Episodes

00:09:16

Mar 18, 2026 | FDA Approves J&J's Oral Psoriasis Pill...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/03/18

FDA approves J&J's Icotyde — the first oral IL-23Rpeptide for psoriasis — with $5B+ peak sales projected. Plus Bicycle Therapeutics shelves lead cancer program zelenectide, Sandoz and Samsung Bioepis partner on five biosimilars, and Eli Lilly slides 7% on a rare HSBCdowngrade.Follow us at: https://thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Icotyde,icotrokinra, Johnson & Johnson, Protagonist

en-us

00:08:55

Mar 17, 2026 | Aldeyra's Third FDA Rejection Crashes...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/03/18

Aldeyra Therapeutics crashes ~68% after the FDA rejectsreproxalap for the third time. CytomX jumps 60%+ on masked ADC data in colorectal cancer. Pfizer's atirmociclib shows 40% PFS reduction in post-CDK4/6 breast cancer. Plus: court blocks RFK Jr. vaccine overhaul, MFN pricingreshapes deal structures, and Bicycle retreats from Padcev. Follow the podcast and visit our site at https://thepharmacloseout.com/#pharma,#pharmaceutical, #FDA, #clinical trials, #biotech, #drug approvals, #healthcare,

en-us

00:09:39

Mar 16, 2026 | Structure Therapeutics Oral GLP-1 Data...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/03/17

Structure's aleniglipron delivers 16.3% weight loss in Phase2 — challenging Lilly's orforglipron in the oral GLP-1 race. Plus BioMarin's Voxzogo safety halt, Aldeyra's reproxalap FDA decision, Rhythm's EMANATE miss ahead of Thursday PDUFA, and Bayer's Kerendia CKD expansion win.Visit us at https://thepharmacloseout.com/#pharma, #pharmaceutical, #FDA, #clinical trials, #biotech, #drug approvals, #healthcare, #pharma podcast, #The Pharma Closeout, #Structure Therapeutics,

en-us

00:12:54

Mar 15, 2026 | Immutep LAG-3 Phase 3 Failure Crashes...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/03/16

Immutep's LAG-3 drug eftilagimod alfa fails Phase 3 futility analysis in NSCLC—stock drops 88%. Ultragenyx DTX301 gene therapy hits co-primary endpoint in OTC deficiency. Plus: Lilly's $3B orforglipron manufacturing expansion, BridgeBio muscular dystrophy data, and four PDUFA dates ahead.Visit at: https://thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, Immutep, eftilagimod alfa, LAG-3, NSCLC, Ultragenyx,

en-us

00:10:14

Mar 13, 2026 | GSK Arexvy Expands to At-Risk Adults...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/03/14

GSK wins FDA clearance to expand Arexvy RSV vaccine to at-risk adults ages 18-49 — the broadest age indication in the RSV market. Plus: Novartis claims the only IL-17A approval for pediatric hidradenitis suppurativa, Pfizer shuts down its small biotech R&D support unit, and why manufacturing is the story to watch as the 2026 patent cliff approachesSubstack: https://thepharmacloseout.substack.comLinkedin: www.linkedin.com/company/the-pharma-closeout#pharma, #pharmaceutical, #FDA, #clinical

en-us

00:10:33

Mar 12, 2026 | Ultragenyx Gene Therapy Hits Phase 3...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/03/13

Ultragenyx's gene therapy clears pivotal trial for raremetabolic disease — a critical win for the gene therapy sector. Lilly invests $3B in China manufacturing for oral GLP-1 and escalates the compounding fight. LAG-3 pioneer fails Phase 3, raising hard questions about the immuno-oncology target. Plus: GSK Arexvy wins expanded RSV approval.Substack: ⁠https://thepharmacloseout.substack.com⁠Linkedin: ⁠www.linkedin.com/company/the-pharma-closeout⁠Substack:

en-us

00:15:45

The AI Reckoning — Episode 4: Who Wins

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/03/12

Three competitive strategies. A $135.7 billion Chineseout-licensing signal. Three diverging regulatory frameworks. We pull together everything from the series into a practical framework: which companies arepositioned to win, which strategic models carry the most risk, and what every pharma professional should be doing right now.Substack: ⁠https://thepharmacloseout.substack.com⁠Linkedin: ⁠www.linkedin.com/company/the-pharma-closeout⁠#pharma, #AI strategy, #competitive advantage, #China pharma,

en-us

00:06:50

Mar 11, 2026 | Vertex Kidney Drug Hits Phase 3;...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/03/12

Vertex clears Phase 3 in kidney disease as after-hoursshares surge. Plus Lilly commits $3B to China GLP-1 manufacturing, UCB's Bimzelx defeats AbbVie's Skyrizi head-to-head, and an FDA approval for fewer than 50 patients worldwide. Wednesday's essential pharma intelligence.#pharma, pharmaceutical, #FDA, #clinical trials, #biotech, drug approvals, #healthcare, #pharma podcast, #The Pharma #Closeout, #Vertex, #kidney disease, #Eli Lilly, #China manufacturing, #GLP-1, #UCB, #Bimzelx,

en-us

00:06:54

Mar 10, 2026 | BioNTech's co-founders just walked away

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/03/11

BioNTech's co-founders just walked away. Both of them. Sameday. They're starting a new mRNA company from scratch. And the FDA approved a drug today without running a clinical trial. That's not a typo — we'll explain the precedent. #pharma, pharmaceutical, #FDA, #clinical trials, #biotech, #drug approvals, #healthcare, #pharma podcast, #The Pharma Closeout, #Pfizer, #Lilly, #Novo Nordisk, #Roche, #GSK, #VertexTags

en-us

00:07:01

Mar 09, 2026 | Novo Nordisk Partners with Hims on...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/03/10

Novo Nordisk and Hims end legal battle, team up for branded GLP-1 telehealth distribution. BMS gets Sotyktu psoriatic arthritis approval and Phase 3 CELMoD win. Incyte receives CRL due to Novo's Indiana manufacturingissues — third company hit by same facility.#pharma,# pharmaceutical, #FDA, #clinical trials, #biotech, #drug approvals, #healthcare, #pharma podcast, #The Pharma Closeout, #Novo Nordisk, #Hims& Hers, #GLP-1, #semaglutide, #Ozempic, #Wegovy, #obesity, #telehealth, #Bristol Myers

en-us

00:16:21

The AI Reckoning — Episode 3: The Agentic Enterprise

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/03/09

Agentic AI is moving from augmenting human work to acting autonomously — monitoring supply chains, adjusting production parameters, generating medical information responses. The EBITDA projections are enormous. So are the risks when an AI agent touches patients. We walk through the deployments, the economics, and the governance gap.#pharma, #agentic AI, #commercial operations, #manufacturing, #digital twins, #supply chain, #EBITDA, #governance, #EU AI Act, #Novo Nordisk, #GSK, #Pfizer

en-us

00:10:58

Weekend Round Up March 08, 2026: Gilead's $7.8B CAR-T...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/03/09

This week, the pharma industry stacked three of the year's biggest deals in five days — and the FDA quietly told us something important about what happens when gene therapy evidence packages get thin. Meanwhile, the GLP-1 wars got more expensive for everyone not named Novo or Lilly. Let's take it apart.

en-us

00:12:13

Mar 06, 2026 | FDA not convinced AMT-130 works;...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/03/07

The FDA told uniQure it is not convinced AMT-130provides any therapeutic benefit in Huntington’s disease — the program now faces a full Phase Three, raising the evidentiary floor for all CNS gene therapy. Moderna jumped fourteen percent on forty-nine percent melanomarecurrence reduction from mRNA-4157 plus Keytruda, combined with resolution of its LNP patent overhang. Servier acquires Day One Biopharmaceuticals fortwo-and-a-half billion dollars; Zealand’s petrelintide obesity data triggers a

en-us

00:12:19

Mar 5, 2026 | Theravance Phase 3 CYPRESS Failure...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/03/06

Theravance Biopharma’s Phase 3 CYPRESS trial of ampreloxetine in neurogenic orthostatic hypotension fails to meet the primary OHSA endpoint at week 8. The company announces a 50% workforce reduction, shuts down R&D, and targets 60% cash burn reduction ($70M annual savings) as it pivots to Yupelri (revefenacin) as its sole commercial asset. Stock drops 26% from $18.95 to $13.96. Science Corporation closes a $230 million Series C at a $1.5 billion valuation for its PRIMA retinal brain-computer

en-us

00:12:02

Mar 4, 2026 | Moderna’s $2.25B LNP Patent Settlement,...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/03/06

Moderna agrees to pay up to $2.25 billion to settle the lipid nanoparticle patent dispute with GenevantSciences and Arbutus Biopharma — $950M upfront in July 2026, with $1.3B contingent on a government contractor immunity appeal under Section 1498. The settlement grants Moderna a global non-exclusive LNP license for infectious disease applications. FDA issues 30 warning letters to telehealth companies overcompounded GLP-1 marketing, its most aggressive enforcement action yet as the shortage-era

en-us

00:19:15

Special Series| AI Reckoning Ep 2: From Molecule to...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/03/05

173 AI-discovered drugs in clinical development. Phase 1 success rates of 80-90% vs 52% traditional. But at Phase 2, the AI advantage disappears — and nobody's talking about it. We unpack rentosertib's Nature Medicine data, zasocitinib's Phase 3 win, the Recursion pipeline reality, synthetic control arms cutting trial timelines by18 months, the FDA's 7-step AI credibility framework, and what this means for R&D careers. Episode 2 of "The AI Reckoning: Pharma's

en-us

00:12:02

Mar 3, 2026 | Novo’s $506M Oral GLP-1 Manufacturing...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/03/03

Novo Nordisk commits €432 million ($506M) to expand oral semaglutide tablet manufacturing in Athlone,Ireland — a supply bet on oral Wegovy’s trajectory as 246,000 patients are already on therapy. Morgan Stanley upgrades Novo from Underweight to Equal Weight,citing ~56% potential upside as a floor call, while Lilly holds a 21-point GLP-1 market share lead (60.5% vs 39.1%). Orforglipron’s Q2 FDA decision is the next test of whether Novo can hold the oral lane. BMS has a PDUFA on Friday for Sotyktu’s

en-us

00:10:18

Mar 2, 2026 | Gilead’s $7.8B CAR-T Bet, YUVIWEL...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/03/03

Gilead acquires Arcellx for $7.8B to challenge J&J’s Carvykti in multiple myeloma with a December FDAdecision approaching. Both Friday decisions resolved: YUVIWEL wins accelerated approval as the first weekly achondroplasia treatment, Dupixent adds AFRS toits ENT franchise. PADCEV plus Keytruda delivers a 47% recurrence reduction in muscle-invasive bladder cancer. CagriSema analyst downgrades continue, and theMarch 20th Rhythm decision could reshape the obesity landscape.

en-us

00:17:38

Mar 1, 2026 | CagriSema Week of Reckoning: Analysts...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/03/03

Seven analyst downgrades, Deutsche Bank at Hold with a 275 DKK target, Morningstar cutting CagriSema peaksales from $13B to $8B. We cover the open-label design limitation constraining Novo's patient-reported outcome claims and where the differentiation argumenthas to go next. Plus GSK's $950M activin bet, China licensing at record pace, Lilly's ACHIEVE-3 win. FDA approved YUVIWEL with a $100–150M PRV. Dupixent'sninth indication. Pfizer/Astellas bladder cancer data that deserved more

en-us

00:10:02

Feb 27, 2026 | CagriSema's New Story After REDEFINE...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/03/03

Novo's CagriSema misses non-inferiority against Zepbound in REDEFINE 4 — approval path intact,differentiation argument shifts to outcomes data. GSK pays $950M for HS235 (35Pharma), a Phase 1 activin inhibitor targeting Merck's Winrevair territory.Lilly's ACHIEVE-3 puts orforglipron decisively ahead of oral semaglutide: 31.4% of patients to near-normal A1C vs 11.7%. Two FDA decisions today: TransCon CNP for achondroplasia and Dupixent's AFRS label expansion.

en-us

121 results

Similar Podcasts

Mothman Podcast

Mothman Podcast

Autobiography of an Electron

Charles R. Gibson

This is a Science Show

Dustin Driver

Get Into Gate: A Stargate Podcast

Get Into Geek

The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 Minutes

BZ Group